4/23
08:47 am
tars
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon [Yahoo! Finance]
Medium
Report
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon [Yahoo! Finance]
4/23
08:30 am
tars
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Medium
Report
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
4/19
07:57 am
tars
Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14% [Yahoo! Finance]
Medium
Report
Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14% [Yahoo! Finance]
4/1
01:42 pm
tars
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why [Yahoo! Finance]
3/7
08:36 pm
tars
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name [Seeking Alpha]
Medium
Report
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name [Seeking Alpha]
3/7
08:02 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $44.00. They now have a "buy" rating on the stock.
Medium
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Jefferies Financial Group Inc. from $30.00 to $44.00. They now have a "buy" rating on the stock.
3/6
11:35 am
tars
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% [Yahoo! Finance]
Low
Report
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% [Yahoo! Finance]
3/5
04:43 pm
tars
Tarsus to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Tarsus to Participate at Upcoming Investor Conferences [Yahoo! Finance]
3/5
04:30 pm
tars
Tarsus to Participate at Upcoming Investor Conferences
Low
Report
Tarsus to Participate at Upcoming Investor Conferences
3/5
08:50 am
tars
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis [Yahoo! Finance]
Medium
Report
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis [Yahoo! Finance]
3/5
08:30 am
tars
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Medium
Report
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
3/1
03:01 pm
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]
Medium
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]
3/1
12:12 am
tars
Tarsus Announces Pricing of $100.0 Million Public Offering [Yahoo! Finance]
Medium
Report
Tarsus Announces Pricing of $100.0 Million Public Offering [Yahoo! Finance]
3/1
12:07 am
tars
Tarsus Announces Pricing of $100.0 Million Public Offering
Medium
Report
Tarsus Announces Pricing of $100.0 Million Public Offering
2/29
04:51 pm
tars
Tarsus Announces Proposed $100.0 Million Public Offering [Yahoo! Finance]
Medium
Report
Tarsus Announces Proposed $100.0 Million Public Offering [Yahoo! Finance]
2/29
04:37 pm
tars
Tarsus Announces Proposed $100.0 Million Public Offering
Medium
Report
Tarsus Announces Proposed $100.0 Million Public Offering
2/29
09:31 am
tars
Thinking about buying stock in Summit Materials, Informatica, Unicycive Therapeutics, Tarsus Pharmaceuticals, or Zion Oil and Gas?
Low
Report
Thinking about buying stock in Summit Materials, Informatica, Unicycive Therapeutics, Tarsus Pharmaceuticals, or Zion Oil and Gas?
2/29
08:17 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $30.00. They now have a "neutral" rating on the stock.
Low
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $30.00. They now have a "neutral" rating on the stock.
2/29
06:51 am
tars
Party Time: Brokers Just Made Major Increases To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Earnings Forecasts [Yahoo! Finance]
Low
Report
Party Time: Brokers Just Made Major Increases To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Earnings Forecasts [Yahoo! Finance]
2/28
02:29 pm
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at HC Wainwright from $50.00 to $57.00. They now have a "buy" rating on the stock.
Low
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at HC Wainwright from $50.00 to $57.00. They now have a "buy" rating on the stock.
2/28
01:30 pm
tars
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy [Yahoo! Finance]
Low
Report
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy [Yahoo! Finance]
2/28
11:16 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Barclays PLC from $40.00 to $50.00. They now have an "overweight" rating on the stock.
Low
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Barclays PLC from $40.00 to $50.00. They now have an "overweight" rating on the stock.
2/28
10:12 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
08:17 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $59.00 price target on the stock, up previously from $55.00.
Low
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $59.00 price target on the stock, up previously from $55.00.
2/28
06:38 am
tars
Tarsus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]